Nature Communications

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

2026-04-17

Full text

DOI https://doi.org/10.1038/s41467-026-72255-5